Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

Channick R, Medrek S, Delcroix M, Gaine S, Jansa P, Lang I, McLaughlin V, Mehta S, Pulido T, Sastry B, Souza R, Torbicki A, Zhao[...]

T cell immune senescence is associated with frailty and sarcopenia in lung transplant candidates

Schaenman JM, Pickering H, Reed EF, Rossetti M, Seligman B, Weigt SS, Shino M, Sayah D, Belperio J, Hu A, Prosper A, Ruchalski K, Ardehali[...]

“It Looks Arterial”: The Chest X-Ray of Nightmares

Chen T. "It Looks Arterial": The Chest X-Ray of Nightmares. Cureus. 2025 Feb 23;17(2):e79532. doi: 10.7759/cureus.79532. PMID: 40144411; PMCID: PMC11937719.